Randomized, Open-Label, Phase 3 Trial of Nivolumab plus Ipilimumab or Nivolumab plus Platinum-Doublet Chemotherapy versus Platinum-Doublet Chemotherapy in Early Stage NSCLC
Phase of Trial: Phase III
Latest Information Update: 04 Dec 2017
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary) ; Carboplatin; Cisplatin; Docetaxel; Gemcitabine; Pemetrexed; Vinorelbine
- Indications Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Acronyms CheckMate 816
- Sponsors Bristol-Myers Squibb; Ono Pharmaceutical
- 02 Oct 2017 Planned number of patients changed from 326 to 642.
- 02 Oct 2017 Planned End Date changed from 8 Mar 2024 to 8 Nov 2028.
- 02 Oct 2017 Planned primary completion date changed from 8 Sep 2019 to 8 May 2023.